Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akseli Hemminki

Showing results (131-140 of 280) with videos related to

Pageof 28
Sort By:
Plos One|August 11, 2017
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatmentLukasz Kuryk, Lotta Vassilev, Tuuli Ranki, et al.
Oncoimmunology|May 8, 2015
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapyIlkka Liikanen, Anniina Koski, Maiju Merisalo-Soikkeli, et al.
Human Gene Therapy|July 3, 2007
Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumorsTanja Hakkarainen, Merja Särkioja, Petri Lehenkari, et al.
International Journal of Cancer|July 22, 2014
GMCSF-armed vaccinia virus induces an antitumor immune responseSuvi Parviainen, Marko Ahonen, Iulia Diaconu, et al.
Cancer Research|March 13, 2002
The flt-1 promoter for transcriptional targeting of teratocarcinomaGerd J Bauerschmitz, Dirk M Nettelbeck, Anna Kanerva, et al.
Molecular Cancer Therapeutics|October 17, 2007
Treatment of metastatic renal cancer with capsid-modified oncolytic adenovirusesKilian Guse, Tuuli Ranki, Martti Ala-Opas, et al.
The Lancet. Haematology|August 5, 2018
Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in SwedenSubhayan Chattopadhyay, Guoqiao Zheng, Amit Sud, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 3, 2011
Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancerAnniina Koski, Mari Raki, Petri Nokisalmi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 19, 2018
Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell TherapyJoão Manuel Santos, Víctor Cervera-Carrascon, Riikka Havunen, et al.
Chemical Communications (Cambridge, England)|August 10, 2012
Synthesis and biological evaluation of unprecedented ring-expanded nucleosides (RENs) containing the imidazo[4,5-d][1,2,6]oxadiazepine ring systemStefano D'Errico, Giorgia Oliviero, Jussara Amato, et al.
Pageof 28

Showing results (131-140 of 280) with videos related to

Sort By:
Pageof 28
Plos One|August 11, 2017
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatmentLukasz Kuryk, Lotta Vassilev, Tuuli Ranki, et al.
Oncoimmunology|May 8, 2015
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapyIlkka Liikanen, Anniina Koski, Maiju Merisalo-Soikkeli, et al.
Human Gene Therapy|July 3, 2007
Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumorsTanja Hakkarainen, Merja Särkioja, Petri Lehenkari, et al.
International Journal of Cancer|July 22, 2014
GMCSF-armed vaccinia virus induces an antitumor immune responseSuvi Parviainen, Marko Ahonen, Iulia Diaconu, et al.
Cancer Research|March 13, 2002
The flt-1 promoter for transcriptional targeting of teratocarcinomaGerd J Bauerschmitz, Dirk M Nettelbeck, Anna Kanerva, et al.
Molecular Cancer Therapeutics|October 17, 2007
Treatment of metastatic renal cancer with capsid-modified oncolytic adenovirusesKilian Guse, Tuuli Ranki, Martti Ala-Opas, et al.
The Lancet. Haematology|August 5, 2018
Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in SwedenSubhayan Chattopadhyay, Guoqiao Zheng, Amit Sud, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 3, 2011
Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancerAnniina Koski, Mari Raki, Petri Nokisalmi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 19, 2018
Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell TherapyJoão Manuel Santos, Víctor Cervera-Carrascon, Riikka Havunen, et al.
Chemical Communications (Cambridge, England)|August 10, 2012
Synthesis and biological evaluation of unprecedented ring-expanded nucleosides (RENs) containing the imidazo[4,5-d][1,2,6]oxadiazepine ring systemStefano D'Errico, Giorgia Oliviero, Jussara Amato, et al.
Pageof 28